

**PUBBLICAZIONI SCIENTIFICHE
PROF. FRANCESCO DOTTA**

1. Amenta F, Cavallotti C, **Dotta F**, Ferrante F, Spinelli F, Vatrella F. (1983) The autonomic innervation of the human greater saphenous vein. Acta Histochemica; 72: 111-116.
2. Di Mario U, Scardellato A, **Dotta F**, Kennedy R, Pozzilli, Andreani D. (1985) T cell phenotype in recent onset and relapsed Graves' disease patients before therapy. In: "Endocrinology '85". Molinatti GM and Martini L (eds), Elsevier Science Publishers BV: 463-467.
3. Di Mario U, Vitillo M, Cavatorta F, Scardellato A, **Dotta F**, Sutherland J, Pozzilli P, Andreani D. (1986) Monitoring immunopathological events in Graves' patients: humoral vs. cellular immune factors as markers of disease activity. In: "The thyroid and autoimmunity". Drexhage HA and Wiersinga WM (eds), Elsevier Science Publishers BV: 64-67.
4. Gargiulo P, Di Mario U, **Dotta F**, Kennedy R, Guy K, Pachi A, Fallucca F. (1986) Activated T cells in normal pregnant women and neonates. Eur J Obstet Gynecol Reprod Biol.; 23: 127-135.
5. Di Mario U, **Dotta F**, Gargiulo P, Sutherland J, Andreani D, Guy K, Pachi A, Fallucca F. (1987) Immunology in diabetic pregnancy: activated T cells in diabetic mothers and neonates. Diabetologia; 30(2): 66-71.
6. **Dotta F**, Gargiulo P, Tiberti C, Pachi A, Fallucca F, Andreani D, Di Mario U. (1987) Humoral and cellular immune abnormalities in neonates of diabetic mothers: any pathological role? Exp Clin Endocrinol.; 89(3): 333-339.
7. Di Mario U, **Dotta F**, Gargiulo P, Fallucca F, Pachi A, Andreani D. (1987) Immunopathology of diabetic mothers and their infants: a contribution to the understanding of islet autoimmunity. In: "The immunology of diabetes". Jaworski (ed), Elsevier Science Publisher B.V.: 137-142.
8. Dib SA, Colman PG, **Dotta F**, Tautkus M, Rabizadeh A, Eisenbarth GS. (1987) Expression of cytoplasmic islet cell antigens by rat pancreas. Diabetes; 36(8): 982-985.
9. Di Mario U, Cavatorta F, Scardellato A, **Dotta F**, Vitillo M, Andreani D (1987) Immunological parameters in patients with Graves' disease before treatment. In: Bianchi (ed), "Thyroid function and dysfunction: Modern concepts", 447- 451.
10. **Dotta F**, Nayak RC, Dib SA, Di Bella E, Krisch K, Posillico JT, Ricker AT, Di Mario U, Eisenbarth GS. (1988) A novel neuroendocrine cell surface glycoprotein: identification, isolation and initial characterization. Endocrinology; 122(4): 1263-1268.
11. Di Mario U, **Dotta F**, Crisa L, Anastasi E, Andreani D, Dib SA, Eisenbarth GS. (1988) Circulating anti-immunoglobulin antibodies in recent-onset type 1 diabetic patients. Diabetes; 37(4): 462-466.
12. Eisenbarth GS, Vardi, Ziegler AG, Colman PG, Nayak RC, **Dotta F**, Jackson RA, Fujii S, Ricker AT, Rabinowe SL, Ikegami H, Soeldner S, Hattori M. (1988) Lessons from the NOD mouse and the BB rat: similarities and contrasts. In: "Animal models in diabetes". Renold AE and Shafrir E (eds); John Libbey, London: 120-123.
13. Colman PG, Di Mario U, Rabizadeh A, **Dotta F**, Anastasi E, Eisenbarth GS. (1988) A prozone phenomenon interferes in islet cell antibody detection: direct comparison of two methods in subjects at risk of diabetes and in insulin dependent diabetics at onset. J Autoimmun.; 1(2): 109-117.
14. Dib SA, Colman PG, **Dotta F**, Tautkus M, Rabizadeh A, Eisenbarth GS. (1988) Assay for cytoplasmic islet cell antibodies using two-color immunofluorescence and rat pancreas. Adv Exp Med Biol.; 246: 63-67.

15. **Dotta F**, Eisenbarth GS. (1989) Type 1 diabetes mellitus: a predictable autoimmune disease with interindividual variation in the rate of beta cell destruction. Clin Immunol Immunopathol.; 50: 85-95.
16. **Dotta F**, Colman PG, Lombardi D, Scharp DW, Andreani D, Pontieri GM, Di Mario U, Lenti L, Eisenbarth GS, Nayak RC. (1989) Ganglioside expression in human pancreatic islets. Diabetes; 38(11): 1478-1483.
17. Gardner SL, **Dotta F**, Nayak RC, George KL, Eisenbarth GS, Halban PA. (1989) Modulation by sodium butyrate of the differentiated status of a clonal pancreatic B-cell line (RIN). Diabetes Res.; 12(2): 93-99.
18. Russo E, Jackson RA, **Dotta F**, Lipes MA, Castano L, Eisenbarth GS. (1990) Type 1 diabetes as a "Mendelian" and "regulated" immune process. in: "Molecular biology of autoimmunity". A.G. Demaine, J. Banga, A.M.McGregor (eds); Springer-Verlag, London: 351-362.
19. Eisenbarth GS, Jackson RA, Ziegler R, Castano L, Bleich D, **Dotta F**. (1990) Predizione e prevenzione del diabete di tipo 1. Il Diabete; 2: 29-34.
20. **Dotta F**, Pozzilli P. (1990) Are islet cell antigens gangliosides? Intl Diab Monitor; 2: 2-3.
21. Previti M, **Dotta F**, Anastasi E, Gianani R, Lenti L, Pontieri GM, Di Mario U. (1991) Autoimmunità insulare nel ratto BB: I gangliosidi pancreatici del ceppo diabete-prono (DP) differiscono da quelli del diabete-resistente (DR). Il Diabete; 3: 309-311.
22. Anastasi E, Perfetti R, Tiberti C, Crisà L, Cabrera E, **Dotta F**, Di Mario U, Andreani D. (1991) Gli autoanticorpi anti-insulina sono realmente indicatori di diabete mellito di tipo 1? Il Diabete; 3: 357-360.
23. **Dotta F**, Previti M, Lenti L, Tiberti C, Anastasi E, Pontieri GM, Appel MC, Andreani D, Di Mario U (1991) Attività beta cellulare ed espressione antigenica nel pancreas di ratto: identificazione di un ganglioside metabolicamente regolabile. Il Diabete, 3: 365-367.
24. **Dotta F**. (1991) Gangliosidi pancreatici, anticorpi polari ed autoimmunità β cellulare. Il Diabete, 3: 254-257.
25. **Dotta F**. (1991) Anti-glucose transporter molecule(s) autoimmunity in type 1 diabetes? Diab Prev Ther.; 5: 3-4.
26. **Dotta F**, Peterson LB, Previti M, Metzger J, Tiberti C, Anastasi E, Zoppitelli, Wicker LS, Di Mario U. (1992) Pancreatic islet ganglioside expression in nonobese diabetic mice: comparison with C57BL/10 mice and changes after autoimmune beta-cell destruction. Endocrinology; 130(1): 37- 42.
27. Rotella C, **Dotta F**, Mannucci E, Di Mario U. (1992) Autoantigens in thyroid and islet autoimmunity: similarities and differences. Autoimmunity, 12(3): 223-237.
28. Previti M, **Dotta F**, Pontieri GM, Di Mario U, Lenti L. (1992) Determination of gangliosides by high-performance liquid chromatography with photodiode-array detection. J Chromat.; 605: 221-225.
29. Wicker LS, Appel MC, **Dotta F**, Pressey A, Miller BJ, DeLarato NH, Fischer PA, Boltz RC, Peterson LB. (1992) Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulitis and cyclophosphamide-induced diabetes. J Exp Med.; 176(1): 67-77.
30. Pozzilli P, Buzzetti R, **Dotta F**, Andreani D. (1992) Acute onset of seeming IDDM in an AIDS patient. Diabetes Care; 15(11): 1824-1825.
31. Di Mario U, **Dotta F**, Purrello F. (1992) Storia naturale del diabete di tipo 1 in fase preclinica. Il

Diabete; 4: 283-86.

32. Cavallo MG, **Dotta F**, Monetini L, Baroni MG, Toto A, Pozzilli P. (1992) Caratterizzazione antigenica di una linea cellulare di insulinoma umano e sua utilizzazione per la valutazione degli anticorpi anti-isola pancreatica. Il Diabete; 4, Suppl.1: 71-74.
33. Previti M, **Dotta F**, Tiberti C, Anastasi E, Lenti L, Pontieri GM, Andreani D, Di Mario U. (1992) Identificazione del ganglioside insulare GM2-1: similitudini con un autoantigene neuronale. Il Diabete, 4, Suppl.1: 91-94.
34. Di Mario U, **Dotta F**. (1992) Natural history and prediction of type 1 diabetes. Ann Ig.; **4**(3): 153-157.
35. **Dotta F**, Tiberti C, Previti M, Anastasi E, Andreani D, Lenti L, Pontieri GM, Gianani R, Appel MC, Eisenbarth GS, Di Mario U. (1993) Rat pancreatic ganglioside expression: differences between a model of autoimmune islet B cell destruction and a normal strain. Clin Immunol Immunopathol.; **66**(2): 143-149.
36. Anastasi E, Tiberti C, Sensi M, Ponte E, Filippetti R, **Dotta F**, Vecchi E, Fiori MG, Di Mario U. (1993) Pancreatic gangliosides delay the onset of insulinitis and hyperglycaemia in the low-dose streptozotocin mouse model. Scand J Immunol.; **37**(3): 308-313.
37. **Dotta F**, Dionisi S, Lollobrigida L, Previti M. (1993) Autoanticorpi ed autoantigeni in un modello animale di distruzione β cellulare: il topo NOD. Giornale It. Diabetol.; Suppl.1: 63-68.
38. Boccuni ML, Bosi E, Buzzetti R, Calafiore R, Cavallo MG, Di Mario U, **Dotta F**, Giordano C, Pozzilli P, Previti M, Richiusa P, Scorsone A, Signore A, Visalli N. (1993) Immunologia ed immunoterapia del diabete mellito di tipo 1. Il Diabete; 5 (Suppl.1): 1-44.
39. Di Mario U, **Dotta F**. (1993) Modulation of antigen expression in relation to intervention strategies in type 1 diabetes. Diabetes Metab Rev.; **9**(4): 245-249.
40. **Dotta F**, Anastasi E, Tiberti C, Di Mario U. (1994) Autoantigens in type 1 diabetes mellitus. J Endocrinol Invest.; **17**(7): 497-508.
41. Dionisi S, **Dotta F**. (1994) Can we replace cytoplasmic ICA determination in diabetes prediction? Diab Prev Ther.; **8**: 36-37.
42. Tiberti C, **Dotta F**, Anastasi E, Torresi P, Multari G, Vecchi E, Andreani D, Di Mario U. (1995) Anti-ganglioside antibodies in new onset type 1 diabetic patients and high risk subjects. Autoimmunity; **22**(1): 43-48.
43. **Dotta F**, Previti M, Lenti L, Dionisi S, Casetta B, D'Erme M, Eisenbarth GS, Di Mario U. (1995) GM2-1 pancreatic islet ganglioside: identification and characterization of a novel islet-specific molecule. Diabetologia, **38**(9): 1117-1121.
44. **Dotta F**, Di Mario U. (1996) Antigenic determinants in type 1 diabetes mellitus. Review article. APMIS.; **104**(11): 769-774.
45. **Dotta F**, Gianani R, Previti M, Lenti L, Dionisi S, D'Erme M, Eisenbarth GS, Di Mario U. (1996) Autoimmunity to the GM2-1 islet ganglioside before and the onset of type 1 diabetes. Diabetes; **45**(9): 1193-1196.
46. Mennuni C, Santini C, **Dotta F**, Farilla L, Di Mario U, Fierabracci A, Bottazzo G, Cortese R, Luzzago A. (1996) Selection of phage-displayed peptides mimicking type 1 diabetes-specific epitopes. J Autoimmunity; **9**(3): 431-436.
47. Cavallo MG, **Dotta F**, Monetini L, Dionisi S, Previti M, Valente L, Toto A, Di Mario U, Pozzilli P. (1996) Beta-cell markers and autoantigen expression by a human insulinoma cell line: similarities to native beta cells. J Endocrinol.; **150**(1): 113-120.

48. **Dotta F**, Di Mario U. (1996) Il diabete mellito di tipo 1 in Sardegna. Scienza e Diabete, 6: 6-7.
49. **Dotta F**, Dionisi S, Farilla L, Di Mario U. (1996) The use of immunological markers in IDDM after more than 20 years from ICA description. Diabetes Metab Rev.; 12(2): 121-126.
50. **Dotta F**, Dionisi S, Misasi R, Tiberti C, Anastasi E, Carabba B, Farilla L, Di Mario U. (1996) Ganglioside antigens in autoimmune diabetes. Diabetes Nutr Metab.; 9: 215-220.
51. **Dotta F**. (1996) Highlights from the American Diabetes Association's Symposium on prevention of type 1 diabetes in the general population. Diab Prev Ther.; 10: 28-29.
52. Misasi R, Dionisi S, Farilla L, Carabba B, Lenti L, Di Mario U, **Dotta F**. (1997) Gangliosides and autoimmune diabetes. Diabetes Metab Rev.; 13(3): 163-179.
53. **Dotta F**, Falorni A, Tiberti C, Dionisi S, Anastasi E, Torresi P, Lernmark A, Di Mario U. (1997) Autoantibodies to the GM2-1 islet ganglioside and to GAD-65 at type 1 diabetes onset. J Autoimmunity; 10(6): 585-588.
54. Tiberti C, Falorni A, Torresi P, Vecchi E, Anastasi E, **Dotta F**, Di Mario U. (1997) A new solid-phase radioimmunoassay to detect anti-GAD65 autoantibodies. J Immunol Methods; 207(2): 107-113.
55. Mennuni C, Santini C, Lazzaro D, **Dotta F**, Farilla L, Fierabracci A, Bottazzo GF, Di Mario U, Cortese R, Luzzago A. (1997) Identification of a novel type 1 diabetes-specific epitope by screening phage libraries with sera from pre-diabetic patients. J Mol Biol.; 268(3): 599-606.
56. Dionisi S, **Dotta F**, Diaz-Horta O, Carabba B, Viglietta V, Di Mario U. (1997) Target antigens in autoimmune diabetes: pancreatic gangliosides. Ann Ist Super Sanità, 33(3): 433-435.
57. **Dotta F**, Previti M, Neerman-Arbez M, Dionisi S, Cucinotta D, Lenti L, Di Mario U, Halban PA. (1998) The GM2-1 ganglioside islet autoantigen in insulin-dependent diabetes mellitus is expressed in secretory granules and is not beta-cell specific. Endocrinology; 139(1): 316-319.
58. Di Mario U, **Dotta F**. (1998) Beta-cell autoimmunity 1998. Diabetes Metab Rev.; 14(1): 1-2.
59. Anastasi E, **Dotta F**, Tiberti C, Vecchi E, Ponte E, Di Mario U. (1999) Insulin prophylaxis down-regulates islet antigen expression and islet autoimmunity in the low-dose Stz mouse model of diabetes. Autoimmunity; 29(4): 249-256.
60. **Dotta F**, Dionisi S, Viglietta V, Tiberti C, Matteoli MC, Cervoni M, Bizzarri C, Marietti G, Testi M, Multari G, Lucentini L, Di Mario U. (1999) T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. Eur J Endocrinol.; 141(3): 272-278.
61. Anastasi E, Ponte E, Gradini R, Bulotta A, Sale P, Tiberti C, Okamoto H, **Dotta F**, Di Mario U. (1999) Expression of Reg and cytokeratin 20 during ductal cell differentiation and proliferation in a mouse model of autoimmune diabetes. Eur J Endocrinol.; 141(6): 644-652.
62. **Dotta F**, Santangelo C, Dionisi S, Viglietta V, Vendrame F, Di Mario U. (1999) Linfociti T, autoreattività e apoptosi: basi immunopatogenetiche del diabete di tipo 1. Il Diabete; 11 (Suppl.): 3-5.
63. Tiberti C, Buzzetti R, Anastasi E, **Dotta F**, Vasta M, Petrone A, Cervoni M, Torresi P, Vecchi E, Multari G, Di Mario U. (2000) Autoantibody negative new onset of type 1 diabetic patients lacking high risk HLA alleles in a caucasian population: are these type 1b diabetes cases? Diabetes Metab Res Rev.; 16(1): 8-14.
64. Marchetti P, **Dotta F**, Ling Z, Lupi R, Del Guerra S, Santangelo C, Realacci M, Marselli L, Di Mario U, Navalesi R. (2000) Function of pancreatic islets isolated from a type 1 diabetic patient. Diabetes Care; 23(5): 701-703.

65. Cilio CM, Bosco S, Moretti C, Farilla L, Savignoni F, Colarizi P, Multari G, Di Mario U, Bucci G, **Dotta F**. (2000) Congenital autoimmune diabetes mellitus. New Engl J Med.; 342(20): 1529-1531.
66. Farilla L, **Dotta F**, Di Mario U, Rapoport B, McLachlan SM. (2000) Presence of interleukin 4 or interleukin 10, but not both cytokines, in pancreatic tissue of two patients with recently diagnosed diabetes mellitus type I. Autoimmunity; 32(3): 161-166.
67. Del Guerra S, Lupi R, **Dotta F**, Marselli L, Lencioni C, Santangelo C, Realacci M, Carmellini M, Mosca F, Navalesi R, Marchetti P. (2000) Effects of prolonged exposure to pancreatic glucagon on the function, antigenicity and survival of isolated human islets. Diabetes Metab Res Rev.; 16(4): 281-286.
68. **Dotta F**. (2000) Meccanismi patogenetici nel diabete autoimmune a lenta insorgenza. Il Diabete; 12: 109-112.
69. Piro S, Lupi R, **Dotta F**, Patané G, Rabuazzo MA, Marselli L, Santangelo C, Realacci M, Del Guerra S, Purrello F, Marchetti P. (2001). Bovine islets are less susceptible than human islets to damage by human cytokines. Transplantation; 71(1): 21-26.
70. Marselli L, **Dotta F**, Piro S, Santangelo C, Masini M, Lupi R, Realacci M, Del Guerra S, Mosca F, Boggi U, Purrello F, Navalesi R, Marchetti P. (2001) Th2 cytokines have a partial, direct protective effect on the function and survival of isolated human islets exposed to combined proinflammatory and Th1 cytokines. J Clin Endocrinol Metab.; 86(10): 4974-4978.
71. Trincavelli ML, Marselli L, Falleni A, Gremigni V, Ragge E, **Dotta F**, Santangelo C, Marchetti P, Lucacchini A, Martini C. (2002) Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets. J Cell Biochem.; 84(3): 636-644.
72. Miao D, Yu L, Tiberti C, Cuthbertson DD, Rewers M, Di Mario U, Eisenbarth GS, **Dotta F**. (2002) ICA512 (IA-2) epitope specific assays distinguish transient from diabetes associated autoantibodies. J Autoimmun.; 18(2): 191-196.
73. **Dotta F**, Vendrame F. (2002) Neonatal syndromes of polyendocrinopathy. Endocrinol Metab Clin North Am.; 31(2): 283-293.
74. Lupi R, **Dotta F**, Marselli L, Del Guerra S, Masini M, Santangelo C, Patané G, Boggi U, Piro S, Anello M, Bergamini E, Mosca F, Di Mario U, Del Prato S, Marchetti P. (2002) Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes; 51(5): 1437-1442.
75. Farilla L, Tiberti C, Luzzago A, Yu L, Eisenbarth GS, Cortese R, **Dotta F**, Di Mario U. (2002) Application of phage display peptide library to autoimmune diabetes: identification of IA-2/ICA512bdc dominant autoantigenic epitopes. Eur J Immunol.; 32(5): 1420-1427.
76. **Dotta F**, Anastasi E. (2002) Nuove fonti di cellule produttrici di insulina. Il Diabete; 14: 128-133.
77. Davidson J, Wilkinson A, Dantal J, **Dotta F**, Haller H, Hernandez D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC; International Expert Panel. (2003) New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an International expert panel meeting. Barcelona, Spain, 19 february 2003. Transplantation; 75(10): 3-24.
78. Tiberti C, Bao F, Bonamico M, Verrienti A, Picarelli A, Di Tola M, Ferri M, Vecchi E, **Dotta F**, Eisenbarth GS, Di Mario U. (2003) Celiac disease-associated transglutaminase autoantibody target domains at diagnosis are age and sex dependent. Clin Immunol.; 109(3): 318-324.

79. Lupi R, Marselli L, Dionisi S, Del Guerra S, Boggi U, Del Chiaro M, Lencioni C, Bugliani M, Mosca F, Di Mario U, Del Prato S, **Dotta F**, Marchetti P. (2004) Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients. Diabetes Metab Res Rev.; 20(3): 246-251.
80. Hui H, **Dotta F**, Di Mario U, Perfetti R. (2004) Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death. J Cell Physiol.; 200(2): 177-200.
81. Falorni A, Laureti S, De Bellis A, Zanchetta R, Tiberti C, Arnaldi G, Bini V, Beck-Peccoz P, Bizzarro A, **Dotta F**, Mantero F, Bellastella A, Betterle C, Santeusano F; SIE Addison Study Group. (2004) Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J Clin Endocrinol Metab.; 89(4): 1598-1604.
82. Marselli L, Trincavelli L, Santangelo C, Lupi R, Del Guerra S, Boggi U, Falleni A, Gremigni V, Mosca F, Martini C, **Dotta F**, Di Mario U, Del Prato S, Marchetti P. (2004) The role of peripheral benzodiazepine receptors on the function and survival of isolated human pancreatic islets. Eur J Endocrinol.; 151(2): 207-214.
83. **Dotta F**, Marchetti P. (2004) Pathological changes in human insulinitis. Curr Opin Endocr & Diabetes; 11: 82-84.
84. Vendrame F, Zappaterreno A, **Dotta F**. (2004) Markers of beta cell function in type 1 diabetes mellitus. Minerva Med.; 95(2): 79-84.
85. Vendrame F, Santangelo C, Misasi R, Dionisi S, Gizzi C, Realacci M, Grasseti D, Di Mario U, **Dotta F**. (2005) Defective lymphocyte caspase-3 expression in type 1 diabetes mellitus. Eur J Endocrinol.; 152(1): 119-125.
86. Santangelo C, Scipioni A, Marselli L, Marchetti P, **Dotta F**. (2005) Suppressor of cytokine signaling gene expression in human pancreatic islets: modulation by cytokines. Eur J Endocrinol.; 152(3): 485-489.
87. Putnam AL, Vendrame F, **Dotta F**, Gottlieb PA. (2005) CD4+CD25 high regulatory T cells in human autoimmune diabetes. J Autoimmun.; 24(1): 55-62.
88. Tiberti C, Verrienti A, Fiore B, Yu L, Eisenbarth GS, **Dotta F**, Di Mario U. (2005) IA-2 combined epitope assay: a new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetes. Clin Immunol.; 115(3): 260-267.
89. Anastasi E, Santangelo C, Bulotta A, **Dotta F**, Argenti B, Mincione C, Gulino A, Maroder M, Perfetti R, Di Mario U. (2005) The acquisition of an insulin-secreting phenotype by HGF-treated rat pancreatic ductal cells (ARIP) is associated with the development of susceptibility to cytokine-induced apoptosis. J Mol Endocrinol.; 34(2): 367-376.
90. Wilkinson A, Davidson J, **Dotta F**, Home P, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregrosa JV, Uchida K, Valentine F, Villamil F, Vincenti F, Wissing M. (2005) Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant.; 19(3): 291-298.
91. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, Corneli RB, Ferretti E, Gulino A, Grasso F, De Simone C, Di Mario U, Falorni A, Boirivant, **Dotta F**. (2005) Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia; 48(8): 1565-1575.
92. **Dotta F**, Fondelli C, Vendrame F, Gianani R. (2005) Pathological changes in human islets. Curr Opin. Endocr & Diabetes; 12: 285-290.
93. Furlanos S, **Dotta F**, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC. (2005) Latent Autoimmune Diabetes in Adults (LADA) should be less latent. Diabetologia;

48(11): 2206-2212.

94. **Dotta F**, Fondelli C, Di Mario U. (2005) Type 1 diabetes mellitus as a polygenic multifactorial disease: immunopathogenic mechanisms of beta-cell destruction. Acta Biomed.; 76 Suppl 3: 14-18.
95. Roep B, Van Halteren A, Boggi U, Marchetti P, **Dotta F**. (2005) Islet autoreactivity in pancreas draining lymph nodes in recent onset type 1 diabetes. Endocr J.; 52: 162-164.
96. Tiberti C, Bonamico M, **Dotta F**, Verrienti A, Di Tola M, Liu E, Ferri M, Nenna R, Picarelli A, Eisenbarth GS. (2006) Evidence of a selective epitope loss of anti-transglutaminase immunoreactivity in gluten-free diet celiac sera: a new tool to distinguish disease-specific immunoreactivities. Clin Immunol.; 121(1): 40-46.
97. Vendrame F, Segni M, Grassetti D, Tellone V, Augello G, Trischitta V, Torlontano M, **Dotta F**. (2006) Impaired caspase-3 expression by peripheral T cells in chronic autoimmune thyroiditis and in autoimmune polyendocrine syndrome-2. J Clin Endocrinol Metab.; 91(12): 5064-5068.
98. **Dotta F**, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, Mosca F, Boggi U, Onetti Muda A, Del Prato S, Elliott JF, Covacci A, Rappuoli R, Roep BO, Marchetti P. (2007) Cocksackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA; 104(12): 5115-5120.
99. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML Bazzigaluppi E, **Dotta F**, Bosi E. (2007) High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care; 30(4): 932-938.
100. Gallo R, Gambelli F, Gava B, Sasdelli F, Tellone V, Masini M, Marchetti P, **Dotta F**, Sorrentino V. (2007) Generation and expansion of multipotent mesenchymal progenitor cells from cultured human pancreatic islets. Cell Death Differ.; 14(11): 1860-1871.
101. Giannakakis K, Massella L, Grassetti D, **Dotta F**, Perez M, Onetti-Muda A. (2007) Type VII collagen in Alport syndrome. Nephrol Dial Transplant.; 22(12): 3501-3507.
102. Marchetti P, **Dotta F**, Lauro D, Purrello F. (2008) An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul Pept.; 146(1-3): 4-11.
103. Bolli G, **Dotta F**, Rochotte E, Cohen SE. (2008) Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab.; 10(1): 82-90.
104. Egan CG, Lavery R, Caporali F, Fondelli C, Laghi-Pasini F, **Dotta F**, Sorrentino V. (2008) Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia; 51(7): 1296-1305.
105. Vendrame F, Verrienti A, Parlapiano C, Filetti S, **Dotta F**, Morano S. (2008) Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. Ann Clin Biochem.; 45(Pt 2): 218-220.
106. Tiberti C, Giordano C, Locatelli M, Bosi E, Bottazzo GF, Buzzetti R, Cucinotta D, Galluzzo A, Falorni A, **Dotta F**. (2008) Identification of tyrosine phosphatase 2 (256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. Diabetes, 57(5): 1276-1283.
107. Bonato V, Barni R, Cataldo D, Collini A, Ruggieri G, De Bartolomeis C, **Dotta F**, Carmellini M. (2008) Analysis of posttransplant diabetes mellitus prevalence in a population of kidney transplant recipients. Transplant Proc. 40(6): 1888-1890.
108. Bruno G, De Micheli G, Fedele D, Monge L, Bonomo M, Consoli A, De Cosmo S, Di Bartolo P, Di Benedetto A, Di Cianni G, **Dotta F**, Giaccari A, Giorgino F, Grassi G, Gruden G,

- Mannino D, Orlandini D, Ponziani MC, Vaccaro O, Vitacolonna E. (2008) Italian standards for diabetes mellitus 2007: executive summary. Acta Diabetol.; 45: 107-127.
109. Gallo R, Grieco FA, Marselli L, Ferretti E, Gulino A, Marchetti P, **Dotta F**. (2008) Hedgehog signaling during expansion of human pancreatic islet-derived precursors. Ann NY Acad Sci.; 1150: 43-45.
 110. **Dotta F**, Fondelli C, Falorni A. (2008) Can NK cells be a therapeutic target in human type 1 diabetes? Eur J Immunol.; 38(11): 2961-2963.
 111. **Dotta F**. (2009) Innate immunity and human insulinitis during beta-cell Coxsackie B4 infection. J Med Virol.; 81: 202.
 112. Tiberti C, Shashaj B, Verrienti A, Vecchi EG, Lucantoni F, Masotti D, Morano S, Sulli N, **Dotta F**. (2009) GAD and IA-2 autoantibody detection in type 1 diabetic patient saliva. Clin Immunol.; 131(2): 271-276.
 113. Bosi E, **Dotta F**, Jia Y, Goodman M. (2009) Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab.; 11(5): 506-515.
 114. Bolli G, **Dotta F**, Colin L, Minic B, Goodman M. (2009) Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab.; 11(6): 589-595.
 115. Bonato V, Cataldo D, **Dotta F**, Carmellini M. (2009) Diagnosis and approach to posttransplant diabetes. Curr Diab Rep.; 9(4): 317-323.
 116. La Marca A, Marzotti S, Brozzetti A, Stabile G, Artenisio AC, Bini V, Giordano R, De Bellis A, Volpe A, Falorni A; Italian Addison Network. (2009) Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. J Clin Endocrinol Metab.; 94(10): 3816-23.
 117. Brozzetti A, Marzotti S, Tortoioli C, Bini V, Giordano R, **Dotta F**, Betterle C, De Bellis A, Arnaldi G, Toscano V, Arvat E, Bellastella A, Mantero F, Falorni A; Italian Addison Network. (2010) Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. Eur J Endocrinol.; 162(2): 361-369.
 118. Roep BO, Kleijwegt FS, van Halteren AG, Bonato V, Boggi U, Vendrame F, Marchetti P, **Dotta F**. (2010) Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol.; 159(3): 338-343.
 119. Igoillo-Esteve M, Marselli L, Cunha DA, Ladrière L, Ortis F, Grieco FA, **Dotta F**, Weir GC, Marchetti P, Eizirik DL, Cnop M. (2010) Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia; 53(7): 1395-1405.
 120. **Dotta F**, Galleri L, Sebastiani G, Vendrame F. (2010) Virus infections: lessons from pancreas histology. Curr Diab Rep.; 10(5): 357-361.
 121. Olivieri A, De Angelis S, Dionisi S, D'Annunzio G, Locatelli M, Marinaro M, Bonato V, Amendola A, Songini M, Velluzzi F, Schirru C, Cotichini R, Stazi MA, **Dotta F**, Lorini R, Bottazzo GF, Boirivant M. (2010) Serum transforming growth factor β 1 during diabetes development in non-obese diabetic mice and humans. Clin Exp Immunol.; 162(3): 407-414.
 122. Merlotti D, Gennari L, **Dotta F**, Lauro D, Nuti R. (2010) Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis.; 20(9): 683-690.
 123. Gallwitz B, Haupt A, Kraus P, Peters N, Petto H, **Dotta F**, Petto H, Poll L, Rose L,

Scherthaner G. (2010) Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al. Diabetes Obes Metab.; 12(12): 1127-1128.

124. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group. (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010 Apr 24; 375(9724):1447-56. Erratum in: Lancet. 2010 Jul 24;376(9737):234.
125. Grieco FA, Vendrame F, Spagnuolo I, **Dotta F.** (2011) Innate immunity and the pathogenesis of type 1 diabetes. Semin Immunopathol.; 33(1): 57-66.
126. Sebastiani G, Vendrame F, **Dotta F.** (2011) MicroRNAs as new tools for exploring type 1 diabetes: relevance for immunomodulation and transplantation therapy. Transplant Proc.; 43(1): 330-332.
127. Falorni A, Chen S, Zanchetta R, Yu L, Tiberti C, Bacosi ML, Furmaniak J, Bini V, **Dotta F**, Eisenbarth GS, Smith BR, Betterle C. (2011) Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. Clin Immunol; 140(3): 291-299.
128. Sebastiani G, Grieco FA, Spagnuolo I, Galleri L, Cataldo D, **Dotta F.** (2011) Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes Metab Res Rev.; 27(8): 862-866.
129. Grieco FA, Moretti M, Sebastiani G, Galleri L, Spagnuolo I, Scafetta G, Gulino A, De Smaele E, Maroder M, **Dotta F.** (2011) Delta-cell specific expression of hedgehog pathway Ptc1 receptor in murine and human endocrine pancreas. Diabetes Metab Res Rev.; 27(8): 755-760.
130. Bruno G, De Micheli A, Frontoni S, Monge L, Bonomo M, De Cosmo S, Grassi G, Nicolucci A, Aiello A, Bertuzzi F, Bonora E, Cimino A, Cordera R, de Bigontina G, Di Bartolo P, **Dotta F**, Frittitta L, Giaccari A, Giorgino F, Gruden G, Marchetti P, Meschi F, Pellegrini MA, Rivellesse A, Sesti G. (2011) Highlights from "Italian Standards of care for Diabetes Mellitus 2009-2010". Nutr Metab Cardiovasc Dis.; 21(4): 302-314.
131. Tancredi M, Marselli L, Lencioni C, Masini M, Bugliani M, Suleiman M, Masiello P, Boggi U, Filipponi F, **Dotta F**, Marchetti P, Di Cianni G. (2011) Histopathology and ex vivo insulin secretion of pancreatic islets in gestational diabetes: A case report. Islets; 3(5): 231-233.
132. Tiberti C, Yu L, Lucantoni F, Panimolle F, Spagnuolo I, Lenzi A, Eisenbarth GS, **Dotta F.** (2011) Detection of four diabetes specific autoantibodies in a single radioimmunoassay: an innovative high-throughput approach for autoimmune diabetes screening. Clin Exp. Immunol.; 166(3): 317-324.
133. Vendrame F, **Dotta F.** (2011) Comment on: Meagher et al. Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. Diabetes 2010;59:2862-2871. Diabetes; 60(2): e12.
134. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. (2011) Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens.; 29(9): 1802-9.
135. Nicolucci A, Del Prato S, Vespasiani G; ELEONOR Study Group. (2011) Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction. Diabetes Care; 34(12): 2524-6.

136. Grieco FA, Sebastiani G, Spagnuolo I, Patti A, **Dotta F**. (2012) Immunology in the clinic review series; focus on type 1 diabetes and viruses: how viral infections modulate beta cell function. Clin Exp Immunol.; 168(1): 24-29.
137. Vendrame F, Cataldo D, Ciarlo L, Umland O, Misasi R, **Dotta F**. (2012) In type 1 diabetes immunocompetent cells are defective in IL-16 secretion. Scand J Immunol.; 75(1): 127-128.
138. Coppieters KT, **Dotta F**, Amirian N, Campbell PD, Kay TW, Atkinson MA, Roep BO, von Herrath MG. (2012) Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med.; 209(1): 51-60.
139. Del Prato S, Nicolucci A, Lovagnini-Scher AC, Turco S, Leotta S, Vespasiani G; ELEONOR Study Group. (2012) Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study. Diabetes Technol Ther.; 14(2): 175-82.
140. Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK; DURATION-4 Study Group (2012) Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care; 35(2): 252-8.
141. Gallo R, Natale M, Vendrame F, Boggi U, Filipponi F, Marchetti P, Laghi Pasini F, **Dotta F**. (2012) In vitro effects of mycophenolic acid on survival, function, and gene expression of pancreatic beta-cells. Acta Diabetol.; 49 Suppl 1: S123-31. PMID: 22249339.
142. Guarino E, Nigi L, Patti A, Fondelli C, **Dotta F**. (2012) Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opin Pharmacother.; 13(9): 1377-84.
143. Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, **Dotta F**, Nuti R. (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab.; 97(5): 1737-1744.
144. Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K, Demetter P, Wasserfall C, Atkinson MA, **Dotta F**, Rottiers P, Gysemans C, Mathieu C. (2012) Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified *Lactococcus lactis* in mice. J Clin Invest.; 122(5): 1717-1725.
145. Gallwitz B, Guzman J, **Dotta F**, Guerci B, Simò R, Basson BR, Festa A, Kiljanski J, Sapin H, Trautmann M, Schernthaner G. (2012) Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet; 379(9833): 2270-2278.
146. Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA, Del Guerra S, D'Aleo V, Piro S, Marselli L, Boggi U, Filipponi F, Tinti L, Salvini L, Wollheim CB, Purrello F, **Dotta F**. (2012) A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia; 55(12): 3262-3272.
147. Galleri L, Sebastiani G, Vendrame F, Grieco FA, Spagnuolo I, **Dotta F**. (2012) Viral Infections and Diabetes. Adv Exp Med Biol; 771: 252-271.
148. Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial). (2012) Addition of either pioglitazone or a sulphonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled

trial. *Nutr Metab Cardiovasc Dis.*; 22(11): 997-1006.

149. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE Investigators (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med*; 367(23): 2204-13.
150. Rissanen A, Howard CP, Botha J, Thuren T, for the Global Investigators (2012) Effect of anti-IL-1 β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. *Diabetes Obes Metabol*; 14:1088-1096.
151. Valle A, Giamporcaro GM, Scavini M, Stabilini A, Grogan P, Bianconi E, Sebastiani G, Masini M, Maugeri N, Porretti L, Bonfanti R, Meschi F, De Pellegrin M, Lesma A, Rossini S, Piemonti L, Marchetti P, **Dotta F**, Bosi E, Battaglia M. (2013) Reduced circulating neutrophils precedes and accompanies type 1 diabetes. *Diabetes*; 62(6): 2072-77. PMID: 23349491.
152. Sebastiani G, Nigi L, Spagnuolo I, Morganti E, Fondelli C, **Dotta F**. (2013) MicroRNA profiling in sera of patients with type 2 diabetes mellitus reveals an upregulation of miR-31 expression in subjects with microvascular complications. *J Biomedical Science and Engineering (JBISE)*; 6: 58-64.
153. Tortosa F, **Dotta F**. (2013) Incretin hormones and beta-cell mass expansion: what we know and what is missing? *Arch Physiol Biochem*. PMID: 23697580; 119(4):161-169.
154. Patti A, Gennari L, Merlotti D, **Dotta F**, Nuti R. (2013) Endocrine actions of osteocalcin. *J Endocrinol*. PMID: 23737779.
155. Spagnuolo I, Patti A, Sebastiani G, Nigi L, **Dotta F**. (2013) The case for virus-induced type 1 diabetes. *Curr Opin Endocrinol Diabetes Obes*. PMID: 23743646; 20(4):292-8.
156. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Morano S, Cavalot F, Lamacchia O, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events Study Group. (2013) HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. *Diabetes care*; 36(8): 2301-10.
157. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) study group. (2013) Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. *J Intern Med.*; 274(2): 176-191.
158. Bosi E, Scavini M, Ceriello A, Cucinotta D, Tiengo A, Marino R, Bonizzoni E, Giorgino F; PRISMA Study Group. (2013) Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial. *Diabetes Care*; 36(10): 2887-94.
159. Ceccarelli E, Guarino E, Merlotti D, Patti A, Gennari L, Nuti R, **Dotta F**. (2013) Beyond glycemic control in diabetes mellitus: effects of incretin-based therapy on bone metabolism. *Front Endocrinol*. doi:10.3389/fendo.2013.00073; 4(73): 1-12.
160. Grieco FA, Moore F, Vigneron F, Santin I, Villate O, Marselli L, Rondas D, Overbergh L, **Dotta F**, Marchetti P, Mathieu C, Eizirik DL. (2013) IL-17A increases the expression of pro-inflammatory chemokines in human pancreatic islets. *Diabetologia*; 57(3): 502-511.
161. Mannucci E, Genovese S, Monami M, Navalesi G, **Dotta F**, Anichini R, Romagnoli F, Gensini G. (2013) Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study. The D.A.N.T.E. (Diabetic ulcer

Antimicrobial New Topical treatment Evaluation) Study. Acta Diabetologica. PMID: 24352342.

162. Ceccarelli E, Patti A, Nigi L, Sebastiani G, Mancarella F, **Dotta F**. (2013) Microbioma intestinale e diabete mellito. Il Diabete; 25: 213-222.
163. Tiberti C, Panimolle F, Bonamico M, Filardi T, Pallotta L, Nenna R, Pontone S, **Dotta F**, Pugliese G, Lenzi A, Balducci S, Morano S. (2014) Long-standing type 1 diabetes: patients with adult-onset develop celiac-specific immunoreactivity more frequently than patients with childhood-onset diabetes, in a disease duration-dependent manner. Acta Diabetologica. PMID: 24452477.
164. **Dotta F**, Sebastiani G. (2014) Enteroviral infections and development of type 1 diabetes: The Brothers Karamazov within the CVBs. Diabetes; 63(2): 384-6.
165. Takiishi T, Ding L, Baeke F, Spagnuolo I, Sebastiani G, Laureys J, Verstuyf A, Carmeliet G, **Dotta F**, Van Belle T, Gysemans C, Mathieu C. (2014) Dietary supplementation with high doses of regular vitamin D3 safely reduces Diabetes incidence in nod mice when given early and long-term. Diabetes. PMID: 24550187.
166. Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, Sebastiani G, Van Huynegem K, Steidler L, Caluwaerts S, Demetter P, Wasserfall CH, Atkinson MA, **Dotta F**, Rottiers P, Van Belle TL, Mathieu C. (2014) Oral delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes. PMID: 24677716.
167. Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Fondelli C, Gruden G, Cavalot F, Lamacchia O, Trevisan R, Vedovato M, Penno G; RIACE Study Group. (2014) Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol;13(1): 59.